Heerspink, Hiddo J.Agarwal, RajivAmor, Antonio J.Bech, Jesper N.Cherney, David Z.Fiorina, PaoloRossing, PeterSchousboe, KarolineRuilope Urioste, Luis MiguelMcGill, Janet B.Et al.2026-07-202026-07-202026Heerspink, H. J. L., Agarwal, R., Amor, A. J., Bech, J. N., Cherney, D. Z. I., Fiorina, P., Rossing, P., Schousboe, K., Selby, N. M., Anker, S. D., Filippatos, G., Pitt, B., Ruilope, L. M., Lawatscheck, R., Brinker, M., Russell, J., Schloemer, P., & McGill, J. B. (2026). Comparing ckd populations with t1d and t2d: A perspective based on the fine-one and fidelity populations. Nephrology Dialysis Transplantation, 41(3), 556-565. https://doi.org/10.1093/ndt/gfaf1830931-05091460-2385https://hdl.handle.net/11268/17293Chronic kidney disease (CKD) is a common comorbidity of both type 1 diabetes (T1D) and type 2 diabetes (T2D) and is associated with increased mortality, end-stage kidney disease and cardiovascular disease risk. Despite standard-of-care treatment with renin– angiotensin system inhibitors added to blood pressure and glycaemic control, people with CKD and T1D have a residual risk of CKD progression. Advances in therapeutic management have been limited over the past 3 decades, especially compared with CKD in T2D, for which new treatment options have emerged in the last 5 years. In this review article we discuss the similarities and differences between T1D and T2D populations with CKD, including epidemiology, pathophysiology and clinical findings. Additionally, we explore the use of albuminuria as a potential bridging biomarker to extrapolate clinical evidence from one population to the other. This concept could offer a promising strategy to narrow the gap in treatment availability between these populations and address the unmet therapeutic need in people with CKD and T1D. The FINE-ONE trial is investigating the non-steroidal mineralocorticoid receptor antagonist finerenone in a population with CKD and T1D using the change in urine albumin:creatinine ratio from baseline over 6 months as its primary endpoint and bridging biomarker. Similarities between the populations from FINE-ONE trial and FIDELITY (a pooled dataset of individuals with CKD and T2D included in two large phase 3 clinical trials of finerenone) may inform the translation of clinical evidence on finerenone from people with CKD and T2D to those with CKD and T1D.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/SaludDiabetesEnfermedades renalesjournal article10.1093/ndt/gfaf183open accessEnfermedad cardiovascularEpidemiologíaMedicina clínicaGoal 3: Ensure healthy lives and promote well-being for all at all ages